Accelerate Diagnostics Inc logo

AXDX

Accelerate Diagnostics Inc

$2.74

Earnings Summary

Revenue
$2.96Mn
Net Profits
$-14.19Mn
Net Profit Margins
-479.55%

Highlights

Revenue:

Accelerate Diagnostics Inc’s revenue jumped 17.47% since last year same period to $2.96Mn in the Q1 2022. On a quarterly growth basis, Accelerate Diagnostics Inc has generated -11.52% fall in its revenue since last 3-months.

Net Profits:

Accelerate Diagnostics Inc’s net profit jumped 41.48% since last year same period to $-14.19Mn in the Q1 2022. On a quarterly growth basis, Accelerate Diagnostics Inc has generated 37.79% jump in its net profits since last 3-months.

Net Profit Margins:

Accelerate Diagnostics Inc’s net profit margin jumped 50.18% since last year same period to -479.55% in the Q1 2022. On a quarterly growth basis, Accelerate Diagnostics Inc has generated 29.7% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Accelerate Diagnostics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.28
EPS Estimate Current Year
-0.28

Highlights

EPS Estimate Current Quarter:

Accelerate Diagnostics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.28 - a 6.67% jump from last quarter’s estimates.

EPS Estimate Current Year:

Accelerate Diagnostics Inc’s earning per share (EPS) estimates for the current year stand at -0.28.

Key Ratios

Key ratios of the Accelerate Diagnostics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.21
Return on Assets (ROA)
-0.56
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Accelerate Diagnostics Inc’s earning per share (EPS) jumped 48.78% since last year same period to -0.21 in the Q1 2022. This indicates that the Accelerate Diagnostics Inc has generated 48.78% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Accelerate Diagnostics Inc’s return on assets (ROA) stands at -0.56.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Accelerate Diagnostics Inc’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Accelerate Diagnostics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.3
-0.21
30%

Company Information

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

Organisation
Accelerate Diagnostics Inc
Headquarters
Tucson, Arizona, US
Employees
224
Industry
Health Technology
CEO
John Phillips